Rigel Pharmaceuticals (NASDAQ:RIGL) has a beta value of 1.36 and has seen 0.14 million shares traded in the last trading session. The company, currently valued at $379.85M, closed the last trade at $21.57 per share which meant it gained $0.71 on the day or 3.40% during that session. The RIGL stock price is -38.25% off its 52-week high price of $29.82 and 65.32% above the 52-week low of $7.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.32 million shares traded. The 3-month trading volume is 267.86K shares.
The consensus among analysts is that Rigel Pharmaceuticals (RIGL) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.48.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
Sporting 3.40% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RIGL stock price touched $21.57 or saw a rise of 2.35%. Year-to-date, Rigel Pharmaceuticals shares have moved 28.24%, while the 5-day performance has seen it change -1.69%. Over the past 30 days, the shares of Rigel Pharmaceuticals (NASDAQ:RIGL) have changed 19.77%. Short interest in the company has seen 0.56 million shares shorted with days to cover at 1.97.
Wall Street analysts have a consensus price target for the stock at $1.5, which means that the shares’ value could drop -1338.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $2.0. In that case, then, we find that the current price level is 90.73% off the targeted high while a plunge would see the stock lose 95.36% from current levels.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
The company’s shares have gained 80.20% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 53.40%.
2 analysts offering their estimates for the company have set an average revenue estimate of 57.59M for the current quarter. 2 have an estimated revenue figure of 44.69M for the next ending quarter. Year-ago sales stood 35.79M and 29.53M respectively for this quarter and the next, and analysts expect sales will grow by 60.89% for the current quarter and 53.40% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.96% over the past 5 years.
RIGL Dividends
Rigel Pharmaceuticals is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders
Insiders own 2.88% of the company shares, while shares held by institutions stand at 68.91% with a share float percentage of 70.95%. Investors are also buoyed by the number of investors in a company, with Rigel Pharmaceuticals having a total of 163.0 institutions that hold shares in the company. The top two institutional holders are BARCLAYS PLC with over 10573.0 shares worth more than $88000.0. As of 2024-06-30, BARCLAYS PLC held 0.006% of shares outstanding.
The other major institutional holder is IFP ADVISORS, INC, with the holding of over 1000.0 shares as of 2024-06-30. The firm’s total holdings are worth over $807.0 and represent 0.0006% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF and Vanguard Total Stock Market Index Fund. As of Nov 30, 2024, the former fund manager holds about 6.08% shares in the company for having 1.07 shares of worth $23.12 million while later fund manager owns 548.78 shares of worth $11.84 million as of Sep 30, 2024, which makes it owner of about 3.12% of company’s outstanding stock.
